Clinical trials, FDA approvals, and pharmaceutical breakthroughs.
Regeneron secured FDA approval for its first-in-class therapy for fibrodysplasia ossificans progressiva (FOP), while Ultragenyx received accelerated approval for a new treatment for Gaucher disease type 1a. The week also saw a flurry of strategic M&A activity, with BioMarin and LEO Pharma acquiring rare disease assets to bolster their pipelines.
An FDA advisory panel narrowly voted to allow compounding pharmacies to produce unapproved peptides BPC-157 and KPV, marking a regulatory shift on biotech innovation. Meanwhile, biopharma dealmaking accelerated in Q2 2026 with M&A nearing $80B and licensing deals hitting a 5-year record, signaling strong market confidence. AI-designed drug candidates continue advancing through clinical trials, with Recursion's REC-4881 demonstrating the first published clinical validation of full-stack AI drug discovery.
The FDA approved Vera Therapeutics' kidney disease treatment for lupus nephritis this week, marking a significant win in autoimmune nephrology. Clinical trial momentum continues across oncology and Alzheimer's disease as biotech enters Q3. Major pharma M&A activity accelerates with Novartis, Vertex, and Ipsen leading the charge post-H1 2026.
The FDA approves oral ensitrelvir for COVID-19 postexposure prophylaxis following positive Phase 3 data, while the agency announces broader regulatory reforms—including acceptance of single-trial evidence for drug approvals—signaling a shift toward expedited pathways. Meanwhile, pharma M&A activity hits record levels, with H1 2026 exceeding $134 billion in deals as big pharma races to refill pipelines; simultaneously, AI-designed biologics enter early clinical evaluation, marking a milestone in computational drug discovery.
The FDA has officially shifted its approval standard to require only one adequate and well-controlled clinical trial for most new drugs, accelerating timelines significantly. Multiple oncology products gained clearance this week including imaging agents and diagnostics. Major pharma acquisitions totaling billions were announced, signaling continued M&A momentum and strategic repositioning across the biopharma sector.
The FDA announced a major shift toward single-trial drug approvals, significantly accelerating the path to market for new medicines. Meanwhile, biotech M&A activity surged to $106 billion—the strongest year since pre-COVID—driven by patent cliff pressures and buoyant markets. AI-designed biologics are now entering clinical evaluation, marking a watershed moment in computational drug discovery.
The FDA announced it will accept single adequate and well-controlled clinical trials as the default standard for new drug approvals, a major regulatory shift toward faster development timelines. BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, expanding its rare disease portfolio with established Fabry and Pompe franchises. Meanwhile, major pharma firms including Pfizer and Eli Lilly are striking unprecedented licensing deals with Chinese biotech companies worth billions.
The FDA has authorized expanded access to daraxonrasib, a RAS inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma, marking a significant compassionate-use milestone for one of oncology's most intractable cancers. Bristol Myers Squibb made the week's biggest deal, inking a $15 billion biobucks partnership with China's Hengrui Pharmaceuticals to advance 13 early-stage programs. Biopharma licensing activity hit a record $82.7 billion in Q1 2026 as the industry shifts toward milestone-heavy deal structures.
The FDA agreed to reconsider Ebvallo, a rare-disease T-cell therapy from Pierre Fabre and Atara Biotherapeutics, after a surprise earlier rejection — with the agency now signaling a single completed trial may suffice for approval. On the deals front, two major transactions reshuffled the industry landscape: Angelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, and Sun Pharma struck an $11.75 billion deal to acquire Organon. Lilly and Gilead continued to lead 2026's M&A surge, with deal volume substantially outpacing last year according to BioPharma Dive.
The FDA's landmark real-time clinical trial pilot—partnering with AstraZeneca and Amgen—marks the most significant regulatory innovation of the week, potentially compressing drug development timelines by collapsing the interval between trial phases. On the deals front, Eli Lilly and Insilico Medicine struck a $2.75 billion AI-driven licensing agreement covering a portfolio of preclinical oral therapeutics, one of the largest AI-pharma partnerships on record. The FDA also granted early expanded access to an unidentified pancreatic cancer drug, drawing broad attention to the desperate unmet need in one of oncology's most lethal diseases.
The FDA moved to fast-track three psychedelic drugs — including psilocybin and methylone — for mental health treatment this week, marking a landmark regulatory shift. AbbVie made a bold $2.1 billion acquisition of Capstan Therapeutics to gain an in vivo CAR T-cell therapy for autoimmune diseases. On the AI front, Isomorphic Labs — the Google DeepMind spinoff — announced it is readying its first AI-designed drug candidates to enter human trials.
This week delivered a string of significant FDA decisions in rare disease, with Travere's Filspari earning the FDA's first-ever approval for focal segmental glomerulosclerosis (FSGS), joining other recent wins in orphan indications. Eli Lilly's Jaypirca scored a Phase 3 CLL trial win demonstrating fixed-duration efficacy, while Regeneron made a bold $2.1B move into radiopharmaceuticals via an Australian partnership with Telix. On the deals front, Garda Therapeutics acquired Assertio and its chemotherapy drug Rolvedon for $125M, and AbbVie escalated its legal battle over the federal 340B drug discount program.
The most impactful regulatory development this week is Amgen's positive Phase 3 TEPEZZA OBI subcutaneous formulation trial in thyroid eye disease, achieving a 77% proptosis response rate. On the deals front, Gilead Sciences made its biggest splash in oncology in years with a $5 billion acquisition of German ADC biotech Tubulis, while Neurocrine Biosciences simultaneously closed its largest-ever M&A transaction by acquiring Soleno Therapeutics for $2.9 billion. Neurology trial watchers are also closely monitoring a fresh set of early 2026 readouts that could reshape CNS treatment pipelines.
Biopharma M&A momentum accelerated dramatically in March, with seven deals worth a combined $29 billion in two weeks, signaling a blockbuster year ahead; Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics as VYKAT XR sales soar; and Q2 2026 is set up as a pivotal regulatory season, headlined by upcoming FDA decisions on Dato-DXd in TNBC and Orca-T in blood cancers.
The FDA's landmark policy shift to accept single-trial evidence for some new drug approvals is reshaping development timelines across the industry. On the deals front, Neurocrine Biosciences announced a $2.9 billion all-cash acquisition of Soleno Therapeutics, bringing a rare disease asset into its portfolio. Meanwhile, Capricor Therapeutics reported positive Phase 3 topline results for deramiocel in Duchenne Muscular Dystrophy, meeting both its primary and key secondary cardiac endpoints.
BioMarin's $4.8 billion all-cash acquisition of Amicus Therapeutics stands as this week's landmark deal, dramatically expanding the rare disease portfolio of both companies. On the regulatory front, FDA novel drug approvals continue to accumulate in Q2 2026, with multiple PDUFA decisions on the horizon. And in clinical trial news, Capricor Therapeutics reported positive topline results from its pivotal Phase 3 HOPE-3 study of deramiocel in Duchenne Muscular Dystrophy, meeting both its primary and key secondary endpoints.
The FDA's approval of Eli Lilly's oral GLP-1 pill Foundayo™ (orforglipron) marks a landmark shift in weight management treatment, representing the first non-injectable GLP-1 receptor agonist cleared for obesity. Biogen made a major strategic bet by entering a $5.6 billion agreement to acquire Apellis Pharmaceuticals, bolstering its complement therapy portfolio. Meanwhile, Capricor Therapeutics reported pivotal Phase 3 HOPE-3 results showing their deramiocel therapy met both the primary endpoint and key cardiac secondary in Duchenne muscular dystrophy.
The FDA made headlines this week with the approval of Foundayo (orforglipron) as the first new molecular entity under the Commissioner's National Priority Voucher program, while the agency also extended its review timeline for Orca-T in hematologic malignancies. On the clinical front, a Phase 3 trial confirmed that durvalumab plus chemotherapy delivers meaningful survival benefits in advanced biliary tract cancer. Meanwhile, biotech licensing deal activity continues to accelerate in 2026, with average deal sizes already up 76% year-over-year.
MAIA Biotechnology reports overall survival exceeding two years for eight patients in an ongoing Phase 2 NSCLC trial, while Merck nears a ~$6 billion acquisition of Terns Pharma to strengthen its cancer portfolio. AbbVie and Gilgamesh Pharmaceuticals struck a major licensing deal worth up to $1.2 billion for a psychiatric disorder candidate, as Q2 2026 looms with several high-stakes FDA decision dates on the horizon.
The most significant regulatory development this week is the FDA's sweeping Q2 2026 decision calendar, headlined by highly anticipated verdicts on obesity, Alzheimer's agitation, and HIV-1 treatments. On the deals front, Otsuka Pharmaceutical's $700 million acquisition of Transcend Therapeutics stands out as the week's largest biopharma transaction. In clinical news, Biogen's lupus drug delivered positive mid-stage skin clearance data and Takeda posted competitive Phase 3 psoriasis results, both reported this morning.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
